利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

322 条记录 (耗时 0.02 秒)

    Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin
    54.
    发明申请
    Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin 审中-公开
    含有阿斯匹林和抗Xa寡糖的组合的组合物和任选与阿司匹林组合的抗Xa寡糖的用途

    公开(公告)号：US20060122151A1

    公开(公告)日：2006-06-08

    申请号：US11269893

    申请日：2005-11-09

    申请人： Roger Cariou

    发明人： Roger Cariou

    IPC分类号： A61K31/737 ,  A61K31/60

    CPC分类号： A61K45/06 ,  A61K31/60 ,  A61K31/616 ,  A61K31/737 ,  A61K2300/00

    摘要： The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty. The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.

    摘要翻译： 本发明涉及合成寡糖，其是通过单独或与阿司匹林联合的抗凝血酶III作用的因子Xa的选择性抑制剂，用于制备用于预防或治疗发生在已经经历过的哺乳动物中的血栓栓塞性疾病的药物 经皮腔内血管成形术。 本发明的主题是用于治疗或预防已经经历经皮腔内血管成形术的哺乳动物中的血栓栓塞性疾病的药物组合物，其包含有效量的至少一种合成寡糖的缔合，所述合成寡糖是选择性因子因子 Xa通过抗凝血酶III起作用，并且有效量的阿斯匹林，任选地与一种或多种药学上可接受的赋形剂混合。

    Disposable injection device
    56.
    发明授权
    Disposable injection device 有权
    一次性注射装置

    公开(公告)号：US06918889B1

    公开(公告)日：2005-07-19

    申请号：US10009264

    申请日：2000-05-25

    申请人： Marc Brunel

    发明人： Marc Brunel

    IPC分类号： A61M5/31 ,  A61M5/28 ,  A61M5/32 ,  A61M5/00

    CPC分类号： A61M5/326 ,  A61M2005/3247 ,  A61M2005/3261

    摘要： A single-use injection device, includes a pre-filled syringe (1), a syringe body (5) which is integral with the said syringe, and a protective case (10), the syringe body and protective case being provided with elements (9, 14, 15, 21) for relative locking in translation, which permit their relative displacement between a position of injection and a position of protection after use. The injection device includes a locking ring (23), which is provided with digital support elements (24), and locking units (25), which can lock the syringe body (5) and the protective case (10), in their position of injection, during injection, and can be displaced axially, such as to permit relative displacement of the syringe body and protective case, towards their position of protection after use, under the effect of the action of resilient member (27), only when the plunger (4) has reached its end of travel.

    摘要翻译： 一次性注射装置包括预填充注射器（1），与所述注射器成一体的注射器主体（5）和保护壳（10），所述注射器主体和保护壳设有元件（ 9,14,15,21）用于相对锁定平移，这允许它们在注射位置和使用后的保护位置之间的相对位移。 注射装置包括设置有数字支撑元件（24）的锁定环（23）和可以将注射器主体（5）和保护壳体（10）锁定在其中的位置的锁定单元（25） 注射期间，并且可以在轴向移动，并且可以在弹性构件（27）的作用的作用下使注射器主体和保护壳体在使用后朝向其保护位置相对移位，只有当柱塞 （4）已经到达旅行的终点。

    Phenoxypropanolamines, preparation and therapeutic use thereof
    59.
    发明授权
    Phenoxypropanolamines, preparation and therapeutic use thereof 失效
    苯氧基丙胺胺，其制备和治疗用途

    公开(公告)号：US06852736B2

    公开(公告)日：2005-02-08

    申请号：US10149626

    申请日：2000-12-15

    申请人： Philippe R. Bovy ,  Roberto Cecchi ,  Olivier Venier

    发明人： Philippe R. Bovy ,  Roberto Cecchi ,  Olivier Venier

    IPC分类号： A61K31/4545 ,  A61K31/5377 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10 ,  A61P15/00 ,  A61P17/02 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24 ,  A61P27/06 ,  C07D401/04 ,  C07D401/14 ,  A61K31/445 ,  C07D211/06 ,  C07D401/06

    CPC分类号： C07D401/04 ,  C07D401/14

    摘要： The invention concerns phenoxypropanolamines of formula (I) in which R1 represents a hydrogen, a group —S(O)z—(C1-C4)alk-R′, (R′ being H, phenyl or (C1-C4)alkoxy), —NHSO2—(C1-C4)alk or NHCO(C1-C4)alk; m and n are each independently 0, 1 or 2; R2 and R3 independently represent a hydrogen, a (C5-C6)alkyl, (C3-C6)cycloalkyl, (C1-C4)alkoxy, hydrogen(C1-C4)alkoxy-(C1-C4)alkyl, mono- or di(C1-C4)alkamino(C1-C4)alkyl, pyrrolidino(C1-C4)alkyl, phenylamino or (C2-C4)alkenyl group, an aromatic or heteroaromatic group optionally substituted with a group R4, an aralkyl or heteroaralkyl group optionally substituted with a group R4, R2 and R3 can also together constitute a saturated or unsaturated ring of 3 to 8 atoms possibly bearing a (C1-C4)alkyl, amino (C1-C4)alkyl, carbamoyl or benzyl substituent; R4 represents a hydrogen or a halogen, or a group —CO(C1-C4)alk or a group —NHSO2—(C1-C4)alk; a group (C1-C4)alk, a group (C1-C4)alkoxy, a halogen, —COOH, —COO(C1-C4)alk, —CN, —CONR3R4, —NO2, —SO2NH2 or —NHSO2(C1-C4)alk; z is 1 or 2; and the salts or solvates thereof. The compounds have agonist activity toward β-3 adrenergic receptors.

    摘要翻译： 本发明涉及式（I）的苯氧基丙醇胺，其中R 1表示氢，-S（O）z - （C 1 -C 4）烷基-R'，（R'为H，苯基或（C 1 -C 4）烷氧基） ，-NHSO 2 - （C 1 -C 4）烷基或NHCO（C 1 -C 4）烷基; m和n各自独立地为0,1或2; R2和R3独立地表示氢，（C5-C6）烷基，（C3-C6）环烷基，（C1-C4）烷氧基，氢（C1-C4）烷氧基 - （C1-C4）烷基， C 1 -C 4烷基，吡咯烷子基（C 1 -C 4）烷基，苯基氨基或（C 2 -C 4）烯基，任选被基团R 4取代的芳族或杂芳族基团，任选被 基团R4，R2和R3也可以一起构成3至8个可能带有（C 1 -C 4）烷基，氨基（C 1 -C 4）烷基，氨基甲酰基或苄基取代基的饱和或不饱和环; R4表示氢或卤素，或基团-CO（C1-C4）烷基或基团-NHSO2-（C1-C4）烷基; （C1-C4）烷基，（C1-C4）烷氧基，卤素，-COOH，-COO（C1-C4）烷基，-CN，-CONR3R4，-NO2，-SO2NH2或-NHSO2（C1- C4）烷基; z为1或2; 及其盐或溶剂合物。 该化合物对β-3肾上腺素能受体具有激动作用。